AZRX - AzurRx BioPharma, Inc. Summary, Stock Quote and News | Benzinga

Market Overview

0.7645 0.011 (1.51%)

Data as of Dec 07, 2019

Prev. Close 0.7531
Price Open 0.75
Volume 76,141
Day's Range 0.75 - 0.7899
52 Wk Range 0.416 - 3.1
50 Day Moving Avg. 0.67
PE Ratio 0
Shares Outstanding 26.64M
Market Cap 20.37M

Trade AZRX stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

AzurRx BioPharma Reports Equity Purchase Deal With Lincoln Park Capital For Up To $15M Benzinga NewsdeskThu, 14 Nov 2019 08:13:33 -0500
AzurRx BioPharma CEO Issues Letter To Shareholders Benzinga NewsdeskTue, 22 Oct 2019 07:12:43 -0500
32 Healthcare Stocks Moving In Friday's Pre-Market Session Lisa LevinFri, 18 Oct 2019 07:34:58 -0500
AzurRx BioPharma Announces Positive CFF DSMB REview Of Final Phase 2 OPTION trial Data Benzinga NewsdeskThu, 17 Oct 2019 11:32:13 -0500
The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings Shanthi RexalineTue, 15 Oct 2019 06:50:13 -0500
AzurRx BioPharma Announces First Patients Dosed In Clinical Study For MS1819-SD In Combination With PERT For Cystic Fibrosis Patients With Severe Exocrine Pancreatic Insufficiency Benzinga NewsdeskTue, 15 Oct 2019 06:31:51 -0500
The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout Shanthi RexalineFri, 11 Oct 2019 07:14:27 -0500
Stocks That Hit 52-Week Lows On Thursday Lisa LevinThu, 10 Oct 2019 10:08:51 -0500
AzurRx Names James Sapirstein CEO Benzinga NewsdeskThu, 10 Oct 2019 06:42:44 -0500
The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave Shanthi RexalineFri, 27 Sep 2019 06:56:12 -0500
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC Globe NewswireNov 14, 2019
AzurRx BioPharma CEO Issues Letter to Shareholders Globe NewswireOct 22, 2019
AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data Globe NewswireOct 17, 2019
AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency Globe NewswireOct 15, 2019
AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer Globe NewswireOct 10, 2019
AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients Globe NewswireSep 25, 2019
AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update Globe NewswireAug 13, 2019
AzurRx BioPharma Announces Closing of $5.0 Million Public Offering of Common Stock ACCESSWIREJul 22, 2019
AzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common Stock ACCESSWIREJul 17, 2019
AzurRx BioPharma Announces Proposed Public Offering of Common Stock Globe NewswireJul 17, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

AzurRx up 31% on stock purchase deal Seeking AlphaNov 14, 2019
AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase — OPTION Trial Data GuruFocusOct 17, 2019
AzurRx Bio launches mid-stage MS1819-SD study in combination with PERT Seeking AlphaOct 15, 2019
New CEO at AzurRx Bio Seeking AlphaOct 10, 2019
AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer GuruFocusOct 10, 2019
AzurRx Bio down 22% premarket on "positive" MS1819 data Seeking AlphaSep 25, 2019
AzurRx BioPharma Announces Positive Results from Phase — Trial with MS–8–9 in Cystic ... GuruFocusSep 25, 2019
AzurRX Biopharma (AZRX) Investor Presentation - Slideshow Seeking AlphaSep 18, 2019
AzurRx BioPharma Reports Second Quarter —…–9 Financial Results and Provides Corporate Update GuruFocusAug 13, 2019
AzurRX Biopharma EPS misses by $0.03 Seeking AlphaAug 13, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q2 2019	EST	Actual	Surprise
EPS:	Expected 2019-08-13
Rev:	Expected 2019-08-13

Q3 2019	EST	Actual	Surprise
EPS:	Expected 2019-11-14
Rev:	Expected 2019-11-14

Company Profile

Read More

Brokerage Center

Compare All Online Brokerages

Book A Demo

Learn How You Can Succeed In The Market With Benzinga Pro

Fastest Market News

Real-Time News Alerts

Customizable News Filters

Book A Demo